PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.38%
Both yoy net incomes decline, with CRVO at -45.66%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-27.15%
Negative yoy D&A while CRVO is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-5631.45%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
0.93%
SBC growth while CRVO is negative at -1.69%. John Neff would see competitor possibly controlling share issuance more tightly.
-32.67%
Negative yoy working capital usage while CRVO is 860.50%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.56%
AP growth well above CRVO's 160.03%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-665.24%
Negative yoy usage while CRVO is 97.21%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
5631.45%
Some yoy increase while CRVO is negative at -112.36%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-36.10%
Both yoy CFO lines are negative, with CRVO at -25.90%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
78.08%
CapEx growth of 78.08% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.08%
Investing outflow well above CRVO's 107.10%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
66.67%
Debt repayment growth of 66.67% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
210.14%
Issuance growth of 210.14% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.